Telomir Pharmaceuticals, Inc. Common StockTELONASDAQ
Loading
SG&A Expenses Over TimeContracting
Percentile Rank75
3Y CAGR+628.7%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+628.7%/yr
Annual compound
Percentile
P75
Within normal range
vs 3Y Ago
387x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$8.10M-15.9%
2024$9.64M+1505.5%
2023$600192.00+2766.1%
2022$20941.00+79.9%
2021$11639.00-